Panuveitis Treatment Global Market Report 2024

The panuveitis treatment market size has grown rapidly in recent years. It will grow from $3.6 billion in 2023 to $3.98 billion in 2024 at a compound annual growth rate (CAGR) of 10.7%. The growth observed during the historic period can be attributed to several factors, including the increased prevalence of uveitis, heightened awareness leading to early diagnosis, advancements in drug delivery systems, advocacy initiatives by patient groups, and support from government entities along with regulatory approvals.

The panuveitis treatment market size is expected to see strong growth in the next few years. It will grow to $5.74 billion in 2028 at a compound annual growth rate (CAGR) of 9.6%. The anticipated growth in the forecast period can be attributed to the adoption of personalized medicine approaches, the emergence of novel therapeutic modalities, an increased focus on patient-centric care, global health preparedness initiatives, precision medicine programs, and changes in healthcare policies. Key trends expected during the forecast period encompass the use of combination therapies for synergistic effects, the widespread adoption of telemedicine and remote monitoring, advancements in imaging technologies, the integration of artificial intelligence in healthcare, and increased global collaborations in research efforts.

The expanding adoption of immunosuppressive therapy is expected to drive the growth of the panuveitis treatment market in the future. Immunosuppressive therapy involves the use of medications that suppress the immune system's response, reducing inflammation in the uvea and managing panuveitis effectively. These therapies play a vital role in mitigating the severity of eye-related diseases, contributing to improved patient outcomes and alleviating symptoms. For instance, in a study published in September 2023 in The Lancet, a UK-based medical journal, immunosuppressive therapies demonstrated significant effectiveness in managing panuveitis, showcasing an increasing trend in their utilization as a preferred treatment option. Therefore, the growing adoption of immunosuppressive therapy is a key driver for the panuveitis treatment market.

Advancements in surgical interventions are anticipated to fuel the growth of the panuveitis treatment market in the coming years. Surgical procedures offer crucial treatment avenues for severe cases of panuveitis, addressing complications and aiding in restoring vision. These interventions encompass techniques such as vitrectomy, surgical removal of the vitreous gel in the eye, and implantation of devices or artificial intraocular lenses to manage panuveitis-related vision impairments. For example, in a clinical report published in June 2023 by the American Academy of Ophthalmology, innovative surgical approaches have shown promising outcomes in treating panuveitis complications, signifying a growing reliance on surgical interventions for managing the condition. Hence, advancements in surgical treatments are propelling the growth of the panuveitis treatment market.

The substantial financial burden posed by the high treatment costs stands as a significant impediment to the growth of the panuveitis market in the forecast period. The expenses associated with panuveitis treatment, inclusive of biologic agents, hospitalizations, outpatient visits, and specialized medical supervision, contribute to the elevated financial burden faced by patients. For instance, as reported in April 2023 by the National Library of Medicine, the comprehensive expenses for medications, surgeries, intravitreal implants, and hospital care collectively amount to an average cost of $69,300 for patients undergoing panuveitis treatment. This considerable financial requirement poses a significant challenge and restrains market growth.

Prominent enterprises engaged in the panuveitis treatment market are directing their efforts towards the development of innovative therapeutic solutions such as Xipere, aimed at providing enhanced and dependable services to their clientele. Xipere (triamcinolone acetonide) represents a corticosteroid administered via suprachoroidal injection to address macular edema induced by ocular inflammation. For instance, in February 2022, Clearside Biomedical Inc., a distinguished biopharmaceutical entity specializing in advanced drug delivery solutions for ocular diseases, introduced Xipere for treating macular edema linked to uveitis and panuveitis in the United States. Being the pioneering approved therapy containing triamcinolone acetonide, Xipere offers a preservative-free, sterile formulation designed specifically for suprachoroidal administration, utilizing Clearside's proprietary microinjector intended for the suprachoroidal space (SCS).

In March 2021, Affibody AB, a biotechnology firm headquartered in Sweden and specializing in tailored therapies for uveitis-related conditions, established a strategic collaboration with Inmagene Biopharmaceuticals. This collaborative effort aimed to introduce izokibep, an interleukin-17 (IL-17) blocker, into the phase 2 clinical development stage for non-infectious intermediate, posterior, and pan-uveitis. Izokibep received approval from the Food and Drug Administration (FDA), a governmental regulatory agency in the United States. Inmagene Biopharmaceuticals, situated in China, is a clinical-stage biotech enterprise concentrating on the development of innovative treatments for immunological and inflammatory disorders, notably panuveitis.

Major companies operating in the panuveitis treatment market report are Pfizer Inc., Johnson and Johnson Pvt. Ltd., Bausch Health Companies Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, Hoffmann-La Roche Ltd., Allergan Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Ltd., Horizon Therapeutics plc, Hikma Pharmaceuticals PLC, Santen Pharmaceutical Co. Ltd., Jubilant Life Sciences Ltd., HanAll Biopharma Inc., Xbrane Biopharma AB, Alimera Science Inc., Ocular Therapeutix Inc., EyeGate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Graybug Vision Inc., Xoma Corporation, Tarsier Pharma Ltd., Vintage Labs Pvt. Ltd., Icon Bioscience Inc., Aciont Inc., Clearside Biomedical Inc., Aldeyra Therapeutics Inc.

North America was the largest region in the panuveitis treatment market in 2023. The regions covered in the panuveitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the panuveitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The panuveitis treatment market consists of revenues earned by entities by providing services such as immunosuppressive therapy, adjunctive therapies, and laser therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The panuveitis treatment market also includes sales of corticosteroids, biogenic agents, and intravitreal implants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The primary drug classes employed in panuveitis treatment include anti-inflammatory medications, antimicrobial drugs, immunotherapy, and targeted therapies. Anti-inflammatory agents are substances or treatments specifically designed to reduce inflammation within the body. These therapeutic interventions can be administered through various routes, including oral and topical applications. Panuveitis treatments are utilized by diverse end-users such as hospitals, home care services, specialty clinics, and others.

The panuveitis treatment market research report is one of a series of new reports that provides panuveitis treatment market statistics, including panuveitis treatment industry global market size, regional shares, competitors with a panuveitis treatment market share, detailed panuveitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the panuveitis treatment industry. This panuveitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.